Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DWJ1567 vs DWC202312 in Healthy Volunteers
NCT06109259Phase 1Recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DWJ1567 in hypercholesterolemia (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at Steady State and Area Under the Concentration-time Curve from Time Zero to Last Quantifiable Concentration. Started Nov 2023; status: recruiting.
02
Drugs
DWJ1567
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06109259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06109259.